Free Newsletter
New hope for cross-species transplantation
Experiments using genetically-engineered pigs to make them compatible with the human immune system are raising expectations about the prospects of cross-species transplantation as an option for patients with diabetes and other currently incurable diseases. However, many scientific hurdles remain before the ultimate goal of inducing long-term tolerance of animal tissues and organs in human recipients, according to a special paper in the journal Transplantation.
"The potential benefits of successful xenotransplantation to large numbers of patients with very differing clinical conditions remain immense, fully warranting the current efforts being made to work towards its clinical introduction," concludes the article. The lead author is Dr. David Cooper of Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center.
- here's the report on the transplantation report
Related Articles:
Early trial backs use of artificial skin tissue. Report
New type of cells developed for tissue repair. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: